Wartko P, Sherman ME, Yang HP, Felix AS, Brinton LA, Trabert B (2013) Recent changes in endometrial cancer trends among menopausal age US women. Cancer Epidemiol 37:374–377

Article  Google Scholar 

Bokhman JV, Chepick OF, Volkova AT, Vishnevsky AS (1981) Adjuvant hormone therapy of primary endometrial carcinoma with oxyprogesterone caproate. Gynecol Oncol 11:371–378

CAS  Article  Google Scholar 

Wright JD, Medel NB, Sehouli J, Fujiwara K, Herzog TJ (2012) Contemporary management of endometrial cancer. Lancet 379:1352–1360

Article  Google Scholar 

Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L (1997) p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 150:177–185

CAS  PubMed  PubMed Central  Google Scholar 

Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R (1982) Uterine papillary serous carcinoma: a highly malignant form of endometrial carcinoma. Am J Surg Pathol 6:93–108

CAS  Article  Google Scholar 

Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, O’Malley DM, Tuller ER, Rose PG, Havrilesky LJ, Moore KN, Huh WK, Axtell AE, Kelley JL, Zanotti KM (2009) UPSC consortium. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol 115:244–248

Article  Google Scholar 

Faratian D, Stillie A, Busby-Earle RM, Cowie VJ, Monaghan H (2006) A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. Int J Gynecol Cancer 16:972–978

CAS  Article  Google Scholar 

Miyamoto M, Takano M, Tsuda H, Soyama H, Aoyama T, Ishibashi H, Kato K, Iwahashi H, Matuura H, Yoshikawa T, Suzuki A, Hirata J, Furuya K (2017) Small foci of serous component as a predictor of recurrence and prognosis for stage IA endometrial carcinomas. Oncology. 93:29–35

Article  Google Scholar 

Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50:373–381

CAS  Article  Google Scholar 

Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 93:136–140

CAS  Article  Google Scholar 

Morello A, Sadelain M, Adusumilli P (2016) Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov 6:133–146

CAS  Article  Google Scholar 

Dainty LA, Risinger JI, Morrison C, Chandramouli GVR, Bidus MA, Zahn C, Rose GS, Fowler J, Berchuck A, Maxwell GL (2007) Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol 105:563–570

CAS  Article  Google Scholar 

Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS (2014) Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early stage lung adenocarcinoma. Clin Cancer Res 20:1020–1028

CAS  Article  Google Scholar 

Einama T, Kawamata F, Kamachi H, Nishihara H, Homma S, Matsuzawa F, Mizukami T, Konishi Y, Tahara M, Kamiyama T, Hino O, Taketomi A, Todo S (2016) Clinical impacts of mesothelin expression in gastrointestinal carcinomas. World J Gastrointest Pathphysiol 7:218–222

Article  Google Scholar 

Ordóñez NG (2003) Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27:1418–1428

Article  Google Scholar 

Kawamata F, Homma S, Kamachi H, Einama T, Kato Y, Tsuda M, Tanaka S, Maeda M, Kajino K, Hino O, Takahashi N, Kamiyama T, Nishihara H, Taketomi A, Todo S (2014) C-ERC/mesothelin provokes lymphatc invasion of colorectal adenocarcinoma. J Gastroenterol 49:81–92

CAS  Article  Google Scholar 

Shiraishi T, Shinto E, Mochizuki S, Tsuda H, Kajiwara Y, Okamoto K, Einama T, Hase K, Ueno H (2019) Mesothelin expression has prognostic value in stage II/III colorectal cancer. Virchows Arch 474:297–307

CAS  Article  Google Scholar 

Nahm CB, Turchini J, Jamieson N, Moon E, Sioson L, Itchins M, Arena J, Colvin E, Howell VM, Pavlakis N, Clarke S, Samra JS, Gill AJ, Mittal A (2019) Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: a multi-institutional cohort study. Eur J Surg Oncol 45:218–224

Article  Google Scholar 

Thomas A, Chen Y, Steinberg SM, Luo J, Pack S, Abdullaev Z, Alewine C, Rajan A, Giaccone G, Pastan I, Miettinen M, Hassan R (2015) High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget 6:11694–11703

Article  Google Scholar 

Li YR, Xian RR, Ziober A, Conejo-Garcia J, Perales-Puchalt A, June CH, Zhang PJ, Tchou J (2014) Mesothelin expression is associated with poor outcomes in breast cancer. Breast Cancer Res Treat 147:675–684

CAS  Article  Google Scholar 

O’Brien TJ, Beard JB, Underwood LJ, Shigemasa K (2002) The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 23:154–169

Article  Google Scholar 

Sl T, James TQ, Sanford CS (1992) Distribution of CA125 in adenocarcinomas: an immunohistochemical study of 481 cases. Am J Clin Pathol 98:175–179

Article  Google Scholar 

Streppel MM, Vincent A, Mukherjee R, Campbell NR, Chen S, Konstantopoulos K, Goggins MG, Seuningen IV, Maitra A, Montgomery EA (2012) Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol 43:1755–1763

CAS  Article  Google Scholar 

Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99:267–277

CAS  Article  Google Scholar 

de la Cuesta R, Maestro ML, Solana J, Vidart JA, Escudero M, Iglesias E, Valor R (1999) Tissue quantification of CA125 in epithelial ovarian cancer. Int J Biol Markers 14:106–114

Article  Google Scholar 

Ginath S, Menczer J, Fintsi Y, Ben-Shem E, Glezerman M, Avinoach I (2002) Tissue and serum CA125 expression in endometrial cancr. Int J Gynecol Cancer 12:372–375

CAS  Article  Google Scholar 

Høgdall EVS, Christensen L, Kjaer SK, Blaakaer J, Kjærbye-Thygesen A, Gayther S, Jacobs IJ, Høgdall CK (2007) CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients from the Danish “MALOVA” ovarian cancer study. Gynecol Oncol 104:508–515

Article  Google Scholar 

Gubbeles JA, Belisle J, Onda M, Rancoourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS (2006) Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5:50

Article  Google Scholar 

Einama T, Kamachi H, Nishihara H, Homma S, Kannno H, Takahashi K, Sasaki A, Tahara M, Okada K, Murakawa S, Kamiyama T, Matsuno Y, Ozaki M, Todo S (2011) Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas 40:1276–1282

CAS  Article  Google Scholar 

Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279:9190–9198

CAS  Article  Google Scholar 

Einama T, Homma S, Kamachi H, Kawamata F, Takehashi K, Takahashi N, Taniguchi M, Kamiyama T, Furukawa H, Matsuno Y, Tanaka S, Nishihara H, Taketomi A, Todo S (2012) Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer 107:137–142

CAS  Article  Google Scholar 

Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Ishikawa M, Kawamata F, Konishi Y, Sato M, Tahara M, Okada K, Muraoka S, Kamiyama T, Taketomi A, Matsuno Y, Furukawa H, Todo S (2015) Importance of luminal membrane mesothelin expression in intraductal papillary mucinous neoplasms. Oncol Lett 9:1583–1589

CAS  Article  Google Scholar 

Slomovites BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, Lu KH (2003) Uterine papillary serous caricinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 91:463–469

Article  Google Scholar 

He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, Rojanasakul Y (2017) Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer 16:63

Article  Google Scholar 

Bhadwaj U, Marin-Muller C, Li M, Chen C, Yao Q (2011) Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/P13K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol Cancer 10:106

Article  Google Scholar 

Hilliard TS (2018) The impact of mesothelin in the ovarian cancer tumor microenvironment. Cancers 10:277

Article  Google Scholar